Guerbet LLC, the US affiliate of Guerbet, a global leader in medical imaging offering a comprehensive range of pharmaceutical products, medical devices, and digital and artificial intelligence (AI) solutions for diagnostic and interventional imaging, will present data on Elucirem (gadopiclenol) injection, Dotarem (gadoterate meglumine) injection and AI solutions at the 2022 Radiological Society of North America (RSNA) Scientific Assembly and Annual Meeting. 

November 26, 2022 — Guerbet LLC, the US affiliate of Guerbet, a global leader in medical imaging offering a comprehensive range of pharmaceutical products, medical devices, and digital and artificial intelligence (AI) solutions for diagnostic and interventional imaging, will present data on Elucirem (gadopiclenol) injection, Dotarem (gadoterate meglumine) injection and AI solutions at the 2022 Radiological Society of North America (RSNA) Scientific Assembly and Annual Meeting. 

"It's very exciting to be back at RSNA, to give the radiology community a first-hand opportunity to experience the clarity of MRI images offered by our new MRI product, Elucirem," said David Hale, Chief Executive Officer of the Guerbet Group. "We look forward to sharing insights about gadopiclenol, a novel, highly stable macrocyclic gadolinium-based contrast agent offering the highest relaxivity in its class for magnetic resonance imaging.2"

Elucirem is indicated for use with MRI in adults and pediatric patients aged two years and older to detect and visualize lesions in the central nervous system (brain, spine and associated tissues) and the body (head and neck, thorax, abdomen, pelvis and musculoskeletal system).1

For Elucirem, Guerbet received Priority Review by the US Food and Drug Administration (FDA) on the basis of the unmet medical needs, as there are currently no U.S. approved and marketed MRI contrast agents indicated for musculoskeletal lesion visualization and no macrocyclic GBCAs approved broadly to visualize lesions located throughout the body.Guerbet received US FDA's marketing approval for Elucirem on September 21, 2022.

Elucirem (gadopiclenol) injection will be available in glass vials, glass pharmacy bulk packages and in plastic pre-filled syringes, which can help to streamline workflow in the imaging suite. All gadopiclenol is manufactured by Guerbet Group Company.

ELUCIREM (gadopiclenol) injection and DOTAREM (gadoterate meglumine) injection Important Safety Information

WARNING:  NEPHROGENIC SYSTEMIC FIBROSIS (NSF)
 

See full prescribing information for complete boxed warning
 

Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities.

  • The risk for NSF appears highest among patients with:
    • Chronic, severe kidney disease (GFR <30 mL/min/1.73 m2), or
    • Acute kidney injury.
  • Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (for example, age >60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.

 

Opportunities to Learn More at RSNA 2022

RSNA Innovation Theater -- @ 1:00 – 1:15 p.m. CST, Monday November 28, 2022: Aashim Bhatia, MD, MS, Assistant Professor in Radiology and Pediatric Neuroradiologist at the Children's Hospital of Philadelphia will be presenting Guerbet's Latest Innovation: Illuminating the Possibilities with a Novel New Drug  https://eppro02.ativ.me/web/planner.?id=RSNA22&table=agenda&tid=S1138

Oral and Poster Presentations:

Title

Author(s)

Date/Time

Session Number

Reduced Body Gd Exposure over 5 months after a single Human Equivalent Dose of Gadopiclenol as compared to Gadobutrol in Healthy Rats

M. Rasschaert, C. Eoulourmyl Strzeminska, C. Walton, M. Lefebvre, N. Decout, C. Factor, P. Robert

Dec. 1 –

12:15 p.m. – 12:45 p.m.

RSA-SPNPM

Efficacy and safety of gadopiclenol for central nervous system (CNS) magnetic resonance imaging (MRI): The Picture Trial

Leo Wolansky

Nov. 30

1:30 p.m. – 2:30 p.m.

W6 – SSNR13

Efficacy and safety of gadopiclenol for central nervous system (CNS) magnetic resonance imaging (MTI): The Picture Trial

Christiane Kuhl

Nov. 27

2:30 p.m. – 3:30 p.m.

S5 – SSMSO1

Use of real life safety data from international pharmacovigilance databases to assess the importance of symptoms associated with gadolinium exposure

Imran Shahid, Eric Lancelot

Dec. 1

12:15 p.m. – 12:45 p.m.

R5A - SPNR

Super-dose: a deep learning method to increase the sensitivity of MRI in neuro-oncology via virtual dose amplification

Alexandre Bone

Dr. Samy Ammari

Thu. Nov. 30

12:45 p.m. – 1:15 p.m.

W5B - SPNR

Multi-head deep learning model for the detection of prostate cancer lesions in bi-parametric MRI

Kourosh Jafari-Khouzani, Maria Victoria Sainz de Cea, Wen Wei, Aly Mohamed, Noelle Debs, Alexandre Routier, Onofrio Caralano, Marwan Sati, Amin Katouzian

Tue, Nov. 29

12:45pm - 1:15pm 

Scientific Poster Sessions

Learning Center –

IN DPS

T5B-SPIN-4

Comparison of three methods for lesion detection and classification on bi-parametric MRI

Maria V. Sainz de Cea, Kourosh Jafari-Khouzani, Wen Wei,

Aly A. Mohamed, Noelie Debs, Alexandre Routier,

Marc-Michel Rohe, Russell Klenk, Onofrio Catalano,

Amin Katouzian

Tue, Nov. 29

9:00am - 9:30am  

Scientific Poster Sessions

Learning Center - GU DPS

T2-SPGU-3

Rigorous Comparison of a New Fully Automated Deep Learning Algorithm for Detection of Focal Liver Lesions in Abdominal Contrast CT with Radiologists

Dufort, G. Palma, P. L. Esquinas Fernandez, Y. Wang, O. Bonakdar Sakhi, F. C. Commandeur,

A. Sitek, F. Louvet-De Verchere, K. Siewert,

K. Tipton

Tue, Nov. 29

1:30pm - 2:30pm  

S401

T6-SSGI10-4

Guerbet's RSNA Education & Research Award Recipient 2022

As part of its continued partnership with the Radiological Society of North America (RSNA), Guerbet is proud to announce that the RSNA Research & Education (R&E) Foundation Board of Trustees has awarded the Guerbet Research Scholar Grant to Vivek Yedavalli, MD, MS from Johns Hopkins School of Medicine. Dr. Yedavalli was awarded $75,000 per year for two years to support his study, Deep Learning Models Using Baseline Comprehensive CT Stroke Collateral Imaging in Cerebral Angiographic Collateral, Post Procedural Hemorrhagic Transformation, and Clinical Outcomes Predictions for Increasing Thrombectomy Eligibility. The RSNA R&E Foundation invests in the future of radiology by developing investigators and supporting lifelong innovative research and education.

Digital Solutions Featured at Booth #1711

Guerbet will also feature a collection of digital and AI software-based products that help to close the loop with the smart connectivity between monitoring and reporting:

  • Dose & Care, a state-of-the-art digital solution for monitoring patient exposure to X-rays that is compatible with all types of ionizing modalities and collects data to provide a record of patient exposure
  • Contrast & Care, an injection data management solution that enables imaging centers to collect, archive, examine, and share injection data, including data on contrast products, adverse events, injector activity, information on estimated glomerular filtration rate, and other risk factors before a clinical exam
  • Icobrain, a cloud-based AI solution designed to quantify disease specific brain structures on MR and CT
  • Galileo, an educational web-based case review platform to help train radiology residents.

For more information: www.guerbet.com

Find more RSNA22 coverage here 


Related Content

News | Artificial Intelligence

February 29, 2024 — AIxSCAN, Inc., a Sunnyvale, CA-based developer of a next generation artificial intelligence (AI) ...

Time February 29, 2024
arrow
News | Women's Health

February 27, 2024 — Hologic, Inc. continues to deliver on its commitment to advancing women’s health by unveiling new ...

Time February 27, 2024
arrow
News | Artificial Intelligence

February 27, 2024 — As artificial intelligence (AI) is increasingly used in radiology, researchers caution that it’s ...

Time February 27, 2024
arrow
Feature | HIMSS | Christine Book

February 26, 2024 — This year’s Healthcare Information and Management Systems Society HIMSS Global Conference and ...

Time February 23, 2024
arrow
News | Breast Imaging

February 23, 2024 — ScreenPoint Medical is showcasing its industry leading Transpara Breast AI at the 2024 European ...

Time February 23, 2024
arrow
Feature | HIMSS | By Christine Book

February 22, 2024 — With just weeks to go before HIMSS 2024, the Global Conference and Exhibition of the Healthcare ...

Time February 22, 2024
arrow
News | Artificial Intelligence

February 22, 2024 — Hartford HealthCare has announced the unveiling of its Center for AI Innovation in Healthcare ...

Time February 21, 2024
arrow
Videos | Information Technology

Industry trade shows and conferences seem to be making their comeback in 2024. And the Healthcare Information and ...

Time February 21, 2024
arrow
News | Computed Tomography (CT)

February 20, 2024 — Ultrahigh-spatial-resolution photon-counting detector CT improved assessment of coronary artery ...

Time February 20, 2024
arrow
News | Breast Imaging

February 20, 2024 — Annual breast cancer screening beginning at age 40 and continuing to at least age 79 results in the ...

Time February 20, 2024
arrow
Subscribe Now